Congratulations on finding a molecule worthy of an Investigational New Drug designation and making it to clinical trials! Now ask yourself: is your clinical supply chain ready to deliver the goods? With the ever-increasing costs of clinical trials and the advantages of being first-to-market, it’s time to take a closer look at your supply chain to ensure it delivers with speed, efficiency, and quality — all within your budget. Unfortunately, many new and emerging biopharmas may not have the required capabilities in-house to meet the challenges. This whitepaper will help guide you through the numerous considerations necessary for you to decide whether to build your capability, outsource it, or create a hybrid in-source/out-source model.